Results of phase I/II trials with recombinant human interleukin-3

Biotechnol Ther. 1991;2(3-4):313-25.

Authors

A Ganser¹, O G Ottmann, G Seipelt, M Eder, G Geissler, R Merget, A Maurer, S Falk, A Lindemann, F Herrmann, et al.

Affiliation

¹ Department of Hematology, University of Frankfurt, Germany.

PMID: 1845133

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Review

MeSH terms

Anemia, Aplastic / therapy
Animals
Bone Marrow Diseases / therapy
Drug Evaluation, Preclinical
Hematopoiesis / drug effects*
Humans
Interleukin-3 / adverse effects
Interleukin-3 / therapeutic use*
Myelodysplastic Syndromes / therapy
Neoplasms / therapy
Recombinant Proteins / adverse effects
Recombinant Proteins / therapeutic use

Substances

Interleukin-3
Recombinant Proteins